Vivasure Medical has received CE mark approval for its PerQseal Elite vascular closure system, providing a new bioresorbable option for percutaneous vessel closure. Vivasure’s device is designed ...

Novocure has obtained CE Mark approval for its Optune Lua device to treat adults with metastatic non-small cell lung cancer (NSCLC) simultaneously with immune checkpoint inhibitors or docetaxel.

Zimmer Biomet (NYSE:ZBH) announced Tuesday that the EU regulators granted CE Mark certification for the company’s RibFix Advantage Fixation System, designed as a less invasive approach to rib ...

(RTTNews) - Roche (RHHBY) announced that it received CE Mark for its Chest Pain Triage algorithm. The algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome or ACS in ...

“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers ...

TEL AVIV, Israel, April 17, 2025 /PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under the ...

We look forward to utilizing this technology to treat our patients." "Securing CE Mark approval for PerQseal Elite marks a major milestone for Vivasure and for patients undergoing complex ...

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, for the identification of epithelial ovarian cancer (EOC ...

[1] European Union: EUR-Lex. Chest Pain Triage algorithm registration [Internet: accesses March 24, 2025] Chest Pain Triage algorithm is an in-vitro diagnostic (IVD) medical device CE-marked (NB 0123) ...

UK digital health firm Vinehealth has won a CE mark for a mobile app that helps cancer patients manage their medications and care, as well as a sister web-based app aimed at clinicians.